Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Nurix Therapeutics, Inc. (NRIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
07/13/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas"
05/04/2023 8-K Quarterly results
04/13/2023 8-K Quarterly results
Docs: "Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment"
03/13/2023 8-K Other Events  Interactive Data
02/09/2023 8-K Quarterly results
Docs: "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Nurix Therapeutics, Inc. presentation",
"Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities"
12/16/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/14/2022 8-K Appointed a new director
Docs: "Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors"
07/08/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
04/07/2022 8-K Quarterly results
Docs: "Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte program"
03/07/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
01/27/2022 8-K Quarterly results
Docs: "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update Advanced four wholly owned and internally developed programs into clinical development"
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Nurix Therapeutics, Inc. presentation",
"Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts"
10/27/2021 8-K Investor presentation
Docs: "Nurix Therapeutics, Inc. presentation",
"Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies"
10/14/2021 8-K Quarterly results
Docs: "Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer"
09/30/2021 8-K Quarterly results
07/13/2021 8-K Quarterly results
07/09/2021 8-K Entry into a Material Definitive Agreement
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 8, 2021 NURIX THERAPEUTICS, INC. Delaware 001-39398 27-0838048 1700 Owens Street, Suite 205 San Francisco, California 94158 660-5320 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 ..."
06/21/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
Docs: "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update First Investigational New Drug application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies"
12/07/2020 8-K Investor presentation
Docs: "Presentation",
"Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy